Latest News and Press Releases

PharmAla Biotech signs contract to supply Harvard neuropsychiatry hospital with MDMA; Appears at CPHI Conference in Milan

PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.

PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1

PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant

PharmAla releases a comprehensive investor update following its Q3 financial release, including highlights such as a 10x revenue increase and patent update

PharmAla launches new educational resource for prescribers of MDMA through the Special Access Program

PharmAla completes private placement and concurrent debt settlement with Advisor.

PharmAla Initiates $750,000 Private Placement with concurrent debt settlement, anticipated to close on April 17th 2024

PharmAla Biotech announces that its Australian Joint Venture, Cortexa, has initiated manufacturing of LaNeo MDMA in Australia.

PharmAla recieves Allowance from USPTO for its lead drug candidate, a next-generation MDMA composition paving the way for clinical trials